Immune related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real world data Journal for ImmunoTherapy of Cancer Adverse Event Reporting Medical School Office of Research Sermorelin Safety Guide Adverse Event Reporting in Clinical Trials In 2023, the FDA banned 19 peptides from compounding pharmacies. No specific safety incident. No clear signal. Just a regulatory decision that pushed millions of patients toward gray market suppliers and overseas